We are back for 2024 with no end of issues to discuss, starting with the HTA review options paper and the coincidence of many reviews and processes delivering outcomes just ahead of the May Budget.
Latest Video
New Stories
-
Amplia enters into preclinical collaboration with Korean drug screening company
November 14, 2024 - - Australian Biotech -
Botanix expands US payer coverage for Sofdra with Ascent Health agreement
November 14, 2024 - - Australian Biotech -
MA proposes CEO for HTA Review implementation group and wants 'continuity'
November 14, 2024 - - Latest News -
Any approach to government relations based on the Montessori method is doomed to fail
November 14, 2024 - - Latest News -
AusBiotech announces the Inaugural Depaz Oration
November 14, 2024 - - Latest News -
Data shows invasive pneumococcal disease at highest level in 15 years
November 13, 2024 - - Latest News -
Arthritis experts launch the ATLAS arthritis eLearning program for health professionals
November 13, 2024 - - Latest News